Center for Cardiovascular Research, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii 96813, USA; email:
Annu Rev Physiol. 2020 Feb 10;82:63-78. doi: 10.1146/annurev-physiol-021119-034527.
Cardiac fibrosis is a pathological condition that occurs after injury and during aging. Currently, there are limited means to effectively reduce or reverse fibrosis. Key to identifying methods for curbing excess deposition of extracellular matrix is a better understanding of the cardiac fibroblast, the cell responsible for collagen production. In recent years, the diversity and functions of these enigmatic cells have been gradually revealed. In this review, I outline current approaches for identifying and classifying cardiac fibroblasts. An emphasis is placed on new insights into the heterogeneity of these cells as determined by lineage tracing and single-cell sequencing in development, adult, and disease states. These recent advances in our understanding of the fibroblast provide a platform for future development of novel therapeutics to combat cardiac fibrosis.
心脏纤维化是一种在损伤和衰老后发生的病理状态。目前,有效减少或逆转纤维化的手段有限。识别抑制细胞外基质过度沉积方法的关键是更好地了解心脏成纤维细胞,这是负责产生胶原蛋白的细胞。近年来,这些神秘细胞的多样性和功能逐渐被揭示。在这篇综述中,我概述了目前用于鉴定和分类心脏成纤维细胞的方法。重点介绍了通过谱系追踪和单细胞测序在发育、成年和疾病状态下确定这些细胞异质性的新见解。这些对成纤维细胞的理解的最新进展为开发新型治疗方法以对抗心脏纤维化提供了平台。